Núñez-Cortés Rodrigo, Calatayud Joaquín, Calonge-Pascual Sergio, Andersen Lars Louis, Bláfoss Rúni, López-Gil José Francisco, López-Bueno Rubén
Department of Physiotherapy, Physiotherapy in Motion Multispeciality Research Group (PTinMOTION), University of Valencia, Valencia, Spain.
Department of Physical Therapy, Faculty of Medicine, University of Chile, Santiago, Chile.
Int J Geriatr Psychiatry. 2025 Aug;40(8):e70137. doi: 10.1002/gps.70137.
To investigate the dose-response relationship between handgrip strength and incidence of Alzheimer's disease (AD) in middle-aged and older adults.
Longitudinal study.
A longitudinal study was conducted in people over 50 years old in 27 European countries and Israel. Data were collected from waves 1, 2, 4, 5, 6, 7 and 8 of the Survey of Health, Ageing and Retirement in Europe (SHARE) between February 2004 and January 2021. Handgrip strength was measured with a hand dynamometer. AD was self-reported based on previous diagnosis. Dose-response associations were assessed by restricted cubic splines.
A total of 85,979 (55.8% female) participants were followed for a median of 9.3 years. Over this time, 3324 (3.9%) developed AD. In the adjusted model, for participants < 65 years, those in the middle third of handgrip strength showed a lower risk of AD compared to the lower third (HR = 0.63, 95% CI: 0.47-0.84), as well as participants in the upper third (HR = 0.63, 95% CI: 0.47-0.85). The spline model determined that the minimum and optimal doses of handgrip strength for a significant reduction in the risk of AD for those aged < 65 years were 54 kg (HR = 0.99; 95% CI: 0.08-0.99) and 56 kg (HR = 0.27; 95% CI: 0.08-0.91), respectively. Among those aged ≥ 65 years, the minimum and optimal doses were 31 kg (HR = 0.69; 95% CI: 0.48-0.99) and 49 kg (HR = 0.57; 95% CI: 0.43-0.76), respectively.
Higher levels of handgrip strength showed a lower risk of developing AD, among adults aged 50 years and over. However, the dose-response relationship is limited to specific ranges according to age group. We identified a range between 54 and 56 kg years and a range between 31 and 49 kg as suitable to prevent AD in adults aged 50-64 and ≥ 65 years, respectively. Routine assessment of hand grip strength can help healthcare professionals identify people at increased risk of AD. Strength-based interventions could provide a practical strategy to support cognitive health and reduce the risk of dementia in clinical practice.
探讨中老年人握力与阿尔茨海默病(AD)发病率之间的剂量反应关系。
纵向研究。
对27个欧洲国家和以色列50岁以上人群进行纵向研究。数据收集于2004年2月至2021年1月期间欧洲健康、老龄化与退休调查(SHARE)的第1、2、4、5、6、7和8轮。使用握力计测量握力。AD根据既往诊断进行自我报告。通过限制性立方样条评估剂量反应关联。
共85979名参与者(55.8%为女性)被随访,中位随访时间为9.3年。在此期间,3324人(3.9%)患AD。在调整模型中,对于<65岁的参与者,握力处于中间三分位的人群患AD的风险低于最低三分位人群(HR = 0.63,95%CI:0.47 - 0.84),也低于最高三分位人群(HR = 0.63,95%CI:0.47 - 0.85)。样条模型确定,对于<65岁人群,显著降低AD风险的握力最小剂量和最佳剂量分别为54 kg(HR = 0.99;95%CI:0.08 - 0.99)和56 kg(HR = 0.27;95%CI:0.08 - 0.91)。在≥65岁人群中,最小剂量和最佳剂量分别为31 kg(HR = 0.69;95%CI:0.48 - 0.99)和49 kg(HR = 0.57;95%CI:0.43 - 0.76)。
50岁及以上成年人中,较高的握力水平显示患AD的风险较低。然而,剂量反应关系因年龄组而异,限于特定范围。我们确定54至56 kg以及31至49 kg的范围分别适合预防50 - 64岁和≥65岁成年人的AD。常规评估握力有助于医疗保健专业人员识别AD风险增加的人群。基于力量的干预措施可为临床实践中支持认知健康和降低痴呆风险提供一种实用策略。